Invetx’s Market Research Study Reveals Nearly 40% of Dogs in the U.S. Suffer from Chronic Osteoarthritis/Pain
Boston, MA, November 29, 2023 – Invetx, a pioneer in protein-based therapeutics for animal health, announced results of a market research study showing that both veterinarians and pet owners would switch to a longer-acting (and higher-priced) therapeutic to treat pain associated with chronic osteoarthritis in their pets.
Invetx Completes Development of Canine and Feline Half-Life Extension Technology Platform that Significantly Extends Duration of Monoclonal Antibody Treatment Effect
Boston, MA- July 25, 2023 – Invetx, a pioneer in protein-based therapeutics for animal health, announced that it has recently completed development of its species-specific, half-life extension technology for dogs and cats which leads to superior extended duration of activity for the company’s veterinary monoclonal antibodies.
Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors
Boston, MA – June 26, 2023- Invetx, a pioneer in protein-based therapeutics for animal health, today announced the appointment of Dr. Marcus Remmers to its board of directors.
Invetx Announces Oversubscribed Series B Financing of $60.5 Million to Advance Portfolio of Best-in-Class Veterinary Biotherapeutics
Company positioned to bring portfolio of novel antibody product candidates through development to market approval Round includes new investors F-Prime Capital, Novo Holdings, GV and
Twist Bioscience Expands Partnership with Invetx to Include Discovery of Best-in-Class Antibodies to Treat Multiple Diseases in Cats and Dogs
SOUTH SAN FRANCISCO and BOSTON, Mass. – November 18, 2021 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering
Boehringer Ingelheim and Invetx Announce Strategic Collaboration to Advance Monoclonal Antibody Biotherapeutics in Animal Health
Collaboration Focused on Discovery, Development and Commercialization of Novel Veterinary Medicines Ingelheim, Germany and Boston, MA- September 27, 2021- Boehringer Ingelheim, a global leader in
Invetx Announces Initiation of First Clinical Study in Dogs with IVX-01, its Novel Monoclonal Antibody Featuring Half-Life Extension
Company Appoints Dr. Robert Zolynas as Vice President, Clinical Development & Regulatory Affairs Boston, MA- September 20, 2021- Invetx, a pioneer in protein-based therapeutics for
Former Head of Boehringer Ingelheim Animal Health, Dr. Joachim Hasenmaier, Joins Invetx Board of Directors
BOSTON, Mass. – January 6, 2021 – Invetx, a pioneer in protein-based therapeutics for animal health, announced today that Dr. Joachim Hasenmaier has joined the
AbCellera and Invetx Expand Multi-Year Antibody Discovery Collaboration in Animal Health
VANCOUVER, British Columbia, and BOSTON, November 19, 2020 – AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that
Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team
New Investors Include Casdin Capital and Tekla Capital Antibody Development Experts Bill Brondyk, PhD, Named Chief Scientific Officer and Colin Giles, PhD, Chief Development
